Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(5 Publications)
Rabbit Recombinant Monoclonal MIP-1 alpha/CCL3 antibody. Suitable for IP, WB, ICC/IF, Flow Cyt (Intra) and reacts with Human, Mouse, Recombinant full length protein - Mouse, Recombinant full length protein - Human samples. Cited in 5 publications.
View Alternative Names
G0S19-1, MIP1A, SCYA3, CCL3, C-C motif chemokine 3, G0/G1 switch regulatory protein 19-1, Macrophage inflammatory protein 1-alpha, PAT 464.1, SIS-beta, Small-inducible cytokine A3, Tonsillar lymphocyte LD78 alpha protein, MIP-1-alpha
- Flow Cyt (Intra)
Unknown
Flow Cytometry (Intracellular) - Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19] (AB229900)
Intracellular flow cytometric analysis of4% paraformaldehyde-fixed, 90% methanol-permeabilized THP-1 (human monocytic leukemia cell line) (untreated, green) / (treated with Phorbol-12-myristate-13-acetate (100ng/ml) for 56h, followed by adding Lipopolysaccharide (1ug/ml) for a further 16h, red) cells labeling Macrophage Inflammatory Protein 1 alpha / CCL3 with ab229900 at 1/500 dilution compared with a Rabbit monoclonal IgG Isotype control details (ab172730) (black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG Fc (Alexa Fluor� 488) preadsorbed (ab150097), at 1/5000 dilution was used as the secondary antibody.
- ICC/IF
Unknown
Immunocytochemistry/ Immunofluorescence - Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19] (AB229900)
Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized THP-1 (human monocytic leukemia cell line) cells labeling Macrophage Inflammatory Protein 1 alpha / CCL3 with ab229900 at 1/100 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing cytoplasmic staining in THP-1 treated with Phorbol-12-myristate-13-acetate (100ng/ml) for 56 h, followed by adding Lipopolysaccharide (1ug/ml) for a further 16 h. The nuclear counter stain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) at 1/200 dilution (red).
Secondary antibody only control : Used PBS instead of primary antibody, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.
Treated : Cells treated with Phorbol-12-myristate-13-acetate (100ng/ml) for 56 h, followed by adding Lipopolysaccharide
(1ug/ml) for a further 16 h.
- Flow Cyt (Intra)
Lab
Flow Cytometry (Intracellular) - Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19] (AB229900)
Flow cytometry staining of human peripheral blood mononuclear cells (PBMCs) (top) or PBMCs treated with LPS 1μg/mL and Brefeldin 1μg/mL for 18 Hours (bottom), with ab229900 (right) or Recombinant Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (left). Cells were fixed and permeabilised with BD Cytofix/Cytoperm™ for 20 min. PBMCs were incubated for 30 mins on ice in 1x PBS containing 10 µg/ml human IgG and 10 % normal goat serum to block FC receptors and non-specific protein-protein interaction followed by the antibody ab229900 or Recombinant Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (1x 106 in 100 µl at 0.04 μg/ml (1/12500 dilution)) for 30 mins at 22°C . The cells were simultaneously stained with CD14.
The secondary antibody Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed was incubated at 1/4000 dilution for 30 mins at 22°C
Acquisition of >30000 events were collected using a 50 mW Blue laser (488nm) and 525/40 bandpass filter. Events were gated on live cells.
- IP
Unknown
Immunoprecipitation - Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19] (AB229900)
Macrophage Inflammatory Protein 1 alpha / CCL3 was immunoprecipitated from 0.35 mg of THP-1 (human monocytic leukemia cell line) (treated with Phorbol-12-myristate-13-acetate (100ng/ml) for 56h, followed by adding Lipopolysaccharide (1ug/ml) for a further 16h ) whole cell lysate with ab229900 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab229900 at 1/1000 dilution.
VeriBlot for IP Detection Reagent (HRP) (ab131366), was used as secondary antibody at 1/5000 dilution.
Lane 1 : THP-1 (human monocytic leukemia cell line) (treated with Phorbol-12-myristate-13-acetate (100ng/ml) for 56h, followed by adding Lipopolysaccharide (1ug/ml) for a further 16h ) whole cell lysate 10 μg (Input).
Lane 2 : ab229900 IP in THP-1 (treated as above) whole lysate.
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab229900 in THP-1 (treated as above) whole cell lysate.
Blocking and dilution buffer and concentration : NFDM/TBST.
Exposure time : 40 seconds.
All lanes:
Immunoprecipitation - Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19] (ab229900)
Observed band size: 12 kDa
false
- WB
Unknown
Western blot - Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19] (AB229900)
Blocking and dilution buffer : 5% NFDM/TBST.
This blot was developed using a higher sensitivity ECL substrate.
The molecular weight observed is consistent with what has been described in the literature (PMID : 11369791)
All lanes:
Western blot - Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19] (ab229900) at 1/1000 dilution
Lane 1:
Untreated THP-1 (human monocytic leukemia cell line) whole cell lysate at 20 µg
Lane 2:
THP-1 (treated with 100 ng/ml phorbol-12-myristate-13-acetate (PMA) for 56 hours, followed by adding 1 μg/ml lipopolysaccharide (LPS) for a further 16 hours ) whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Observed band size: 12 kDa
false
Exposure time: 3min
- WB
Unknown
Western blot - Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19] (AB229900)
Blocking / Dilution buffer and concentration : 5% NFDM/TBST
All lanes:
Western blot - Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19] (ab229900) at 1/1000 dilution
Lane 1:
Untreated RAW 264.7 (mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate at 20 µg
Lane 2:
RAW 264.7 treated with 100 ng/ml LPS for 3 hours and then 300 ng/ml Brefeldin A was added for the last 3 hours, whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Observed band size: 12 kDa
false
- WB
Lab
Western blot - Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19] (AB229900)
Exposure time :
Lane 1-5 20 seconds ; Lane 6-7 3 seconds
All lanes:
Western blot - Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19] (ab229900) at 1/1000 dilution
Lane 1:
His-tagged mouse CCL3 Recombinant Protein
Lane 2:
His-tagged human CCL3 Recombinant Protein
Lane 3:
His-tagged human CCL4 Recombinant Protein
Lanes 4 - 5:
His-tagged human CCL18 Recombinant Protein
Lane 6:
GST-tagged human CCL3L1 Recombinant Protein
Lane 7:
GST-tagged human CCL4L1 Recombinant Protein
false
Related conjugates and formulations (4)
-
Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19] - BSA and Azide free
-
665 Alexa Fluor® 647
Alexa Fluor® 647 Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19]
-
519 Alexa Fluor® 488
Alexa Fluor® 488 Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19]
-
578 PE
PE Anti-MIP-1 alpha/CCL3 + CCL3L1 antibody [EPR22529-19]
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The MIP-1 alpha functions as a chemotactic cytokine. It binds to receptors like CCR1 and CCR5 on the surface of target cells resulting in activation and migration toward areas of inflammation. MIP-1 alpha does not form a complex with other proteins; however its interactions with its receptors are vital for signal transduction. It also promotes the production of additional inflammatory cytokines contributing to amplifying immune responses. The chemotactic properties of MIP-1 alpha make it an important player in the body's defense against pathogens.
Pathways
MIP-1 alpha is involved in important immune pathways like the NF-kB signaling pathway. This pathway plays a significant role in immune cell activation and the inflammatory response. MIP-1 alpha interacts with other chemokines like CCL4 (MIP-1 beta) which shares similar functions and binds to CCR5. The coordinated activities of these chemokines enhance the recruitment and activation of various leukocyte populations facilitating an effective immune response.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Additional targets
Publications (5)
Recent publications for all applications. Explore the full list and refine your search
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 12:e2411375 PubMed40213993
2025
Applications
Unspecified application
Species
Unspecified reactive species
Clinical & experimental metastasis 42:12 PubMed39856383
2025
Applications
Unspecified application
Species
Unspecified reactive species
PloS one 18:e0287829 PubMed37910521
2023
Applications
Unspecified application
Species
Unspecified reactive species
Environmental toxicology 38:172-184 PubMed36346222
2022
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in pharmacology 12:551839 PubMed33953665
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com